Abstract
Effect of advanced glycation end products (AGEs) in the pathogenesis of cancer could be diminished by interaction with soluble RAGE or by reducing AGE-precursors via glyoxalase I. Glu111Ala polymorphism of glyoxalase I gene, AGEs, and sRAGE serum levels were studied in 113 breast cancer patients and in 58 controls. Higher frequency of the mutated C allele was found in patients with negative estrogen receptors and in patients in clinical stage III compared to controls (P< 0.05). The presence of the C allele could represent a negative prognostic factor; however, further studies are needed to confirm this hypothesis.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Breast Neoplasms / enzymology
-
Breast Neoplasms / genetics*
-
Breast Neoplasms / pathology
-
Case-Control Studies
-
Female
-
Gene Expression Regulation, Enzymologic*
-
Gene Expression Regulation, Neoplastic*
-
Gene Frequency
-
Genotype
-
Glycation End Products, Advanced / blood
-
Humans
-
Lactoylglutathione Lyase / genetics*
-
Middle Aged
-
Neoplasm Staging
-
Phenotype
-
Polymorphism, Single Nucleotide*
-
Prognosis
-
Receptor for Advanced Glycation End Products
-
Receptors, Estrogen / analysis
-
Receptors, Immunologic / blood
Substances
-
Glycation End Products, Advanced
-
Receptor for Advanced Glycation End Products
-
Receptors, Estrogen
-
Receptors, Immunologic
-
Lactoylglutathione Lyase